BGB-3111_BGB-A317_Study_001

Completed

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Beigene Study ID info

BGB-3111_BGB-A317_Study_001

ClinicalTrials.gov ID info

Clinical Drug Trials ID info

CTR20180193

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents